At the time of writing, it is still early in 2026. This year’s major pharmaceutical blockbusters are expected to be two obesity drugs. As before, Novo Nordisk and Eli Lilly are leading development in the field.
According to analysis firm Evaluate, Novo’s dual-acting injectable CagriSema and Lilly’s oral drug orforglipron are projected to generate revenues of USD 17.2 billion and USD 11.8 billion respectively through 2032. Both drugs could be approved in the US this year and likely in the EU in 2027.
BREAKING